Keyphrases
Epidermal Growth Factor Receptor
100%
Prostate Cancer
100%
Tumor Protein p53 (TP53)
100%
Androgen Resistance
100%
Aurora Kinase A (AURKA)
100%
Castration-resistant Prostate Cancer
66%
Nuclear EGFR
66%
Anti-androgen Therapy
50%
Cancer Resistance
16%
Nuclear Localization
16%
Therapeutic Approaches
16%
Clinical Trials
16%
Biological Insight
16%
Successful Completion
16%
Kinase-independent
16%
Receptor-targeted Therapy
16%
Therapeutic Leads
16%
Degrader
16%
Patient-derived Xenograft
16%
Transgenic Mouse Model
16%
Small Molecules
16%
Clinical Samples
16%
Chemical Tools
16%
Resistant Disease
16%
Tumor
16%
Chemotherapy Resistance
16%
Abiraterone
16%
Rational Therapeutics
16%
Growth Factor Receptor Tyrosine Kinase
16%
Enhanced Resistance
16%
Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor (EGFR-TKI)
16%
Resistance Acquisition
16%
Enzalutamide Resistance
16%
Therapy Resistance
16%
Castration-resistant
16%
Enzalutamide
16%
Advanced Prostate Cancer
16%
Clinical Problems
16%
Pharmacology, Toxicology and Pharmaceutical Science
Antiandrogen
100%
Prostate Cancer
100%
Epidermal Growth Factor Receptor
100%
Castration Resistant Prostate Cancer
36%
Enzalutamide
18%
Epidermal Growth Factor Receptor Kinase Inhibitor
9%
Abiraterone
9%
Clinical Trial
9%
Phosphotransferase
9%
Therapy Resistance
9%
Transgenic Organism
9%
Neoplasm
9%
Diseases
9%